According to Stratistics MRC, the Global Artemisinin Combination Therapy (ACT) market is accounted for $338.80 billion in 2017 and is expected to reach $830.98 billion by 2026 growing at a CAGR of 10.5% during the forecast period.
— Rising pipeline for new anti-malarial drugs, growing demand for artemisinin combination therapy (ACT) and increasing government initiatives are few factors propelling for the growth of the market. However, limited number of manufacturers globally acts as a hindrance for the market growth.
Request for sample here: https://www.strategymrc.com/report/artemisinin-combination-market/request-sample
Based on type, Artesunate–Mefloquine is a lucrative market for Artemisinin Combination Therapy (ACT) due to its quick spread of resistance, mediated mainly by a raise in copy number and expression of the P. falciparum multi-drug resistance (MDR) gene. This improves bioavailability and reduces vomiting. There is no formulation of mefloquine for children. Regardless of earlier restrictions there is no cause to withhold mefloquine for young children. Limited information recommends that mefloquine is perhaps secure in pregnancy.
By geography, Middle East and Africa held the largest market share in the artemisinin combination therapy owing to have large number of production base of artemisinin herbs and growing demand in malaria endemic countries which are contributing to the expansion of the market in MEA. Though African countries, where the occurrence of malaria is high, so they have amplified malaria control strategies, efficient treatment and control, but it still presents a huge logistical difficulty. As numerous at-risk people survive in extreme poverty in isolated areas, WHO and other organizations are working on completely eradicating it in Africa and thus, over the coming years, the adoption rate of ACT is further expected to boost.
Access the complete report at: https://www.strategymrc.com/report/artemisinin-combination-market
Some of the key players profiled in the Artemisinin Combination Therapy (ACT) market include KPC Pharmaceuticals, Inc., Shanghai Fosun Pharmaceutical Industrial Development Company Limited, Sanofi, Desano Holdings Ltd., Calyx Chemicals and Pharmaceuticals Limited, Mylan N.V., Novartis AG, Denk Pharma GmbH & Co. KG, Hovid Berhad, Ipca Laboratories Limited, Cipla Limited and Aspen Pharmacare Holdings Limited.
Make an inquiry at: https://www.strategymrc.com/report/artemisinin-combination-market
• North America
o Rest of Europe
• Asia Pacific
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Follow us on Twitter: https://twitter.com/StratisticsMRC
Follow us on LinkedIn at: https://www.linkedin.com/company/stratistics-market-research-consulting-pvt-ltd?trk=mini-profile
About Stratistics MRC
We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends.
Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects.
Release ID: 464861